| Literature DB >> 24879417 |
Silvia Llopis1, Carolina Hernández-Haro2, Lucía Monteoliva2, Amparo Querol1, María Molina2, María T Fernández-Espinar1.
Abstract
Saccharomyces cerevisiae plays a beneficial role in health because of its intrinsic nutritional value and bio-functional properties, which is why it is also used as a dietary supplement. However, the perception that S. cerevisiae is harmless has changed due to an increasing number of infections caused by this yeast. Given this scenario, we have tested whether viable strains contained in dietary supplements displayed virulence-associated phenotypic traits that could contribute to virulence in humans. We have also performed an in vivo study of the pathogenic potential of these strains using a murine model of systemic infection by intravenous inoculation. A total of 5 strains were isolated from 22 commercial products and tested. Results highlight one strain (D14) in terms of burden levels in brains and kidneys and ability to cause death, whereas the other two strains (D2 and D4) were considered of low virulence. Our results suggest a strong relationship between some of the virulence-associated phenotypic traits (ability to grow at 39°C and pseudohyphal growth) and the in vivo virulence in a mouse model of intravenous inoculation for isolates under study. The isolate displaying greatest virulence (D14) was evaluated in an experimental murine model of gastrointestinal infection with immunosuppression and disruption of mucosal integrity, which are common risk factors for developing infection in humans, and results were compared with an avirulent strain (D23). We showed that D14 was able to spread to mesenteric nodes and distant organs under these conditions. Given the widespread consumption of dietary supplements, we recommend only safe strains be used.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24879417 PMCID: PMC4039445 DOI: 10.1371/journal.pone.0098094
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Commercial products analyzed in this study.
| Product code | Commercial name | Presentation | Company |
| D1 | “Levadura de cerveza y germen de trigo” | Pills | ALTANA PHARMA, S.A. |
| D2 | Levivel | Pills | NOVA DIET, S.A. |
| D3 | “Levadura de cerveza” | Pills | ARKOPHARMA |
| D4 | “Levadura” | Pills | ALTANA PHARMA, S.A. |
| D5 | “Ultra-Levura” ( | Pills | UPSAMEDICA, S.L. |
| D6 | “Levadura de cerveza” | Liquid | INSTITUTO FERRÁN |
| D7 | Levadiet | Pills | DIETISA |
| D8 | “Levadura de cerveza” | Flakes | TERRA VERDA |
| D9 | “Levadura de cerveza” | Pills | TERRA VERDA |
| D10 | Bioland beer | Liquid | BRAUEREI SCHLESWIG |
| D11 | Panaktiv | Liquid | Dr. H. Metz |
| D12 | “Levadura y germen” | Pills | SOTYA, S.A. |
| D13 | Strath | Pills | DIETISA |
| D14 | Phytodepur | Pills | Dietéticos INTERSA, S.A. |
| D15 | “Levadura copos” | Flakes | RAPUNZEL |
| D16 | “Levadura viva + selenio” | Pills | NATURLIFE, S.L. |
| D17 | Depurator | Liquid | INTERSA, S.A. |
| D18 | Levatrig | Pills | BIOSERUM Laboratorios S.L. |
| D19 | “Levadura de cerveza” | Pills | Distribuciones FELIU |
| D20 | Phytonorm | Pills | INTERSA, S.A. |
| D21 | “Levadura de cerveza” | Flakes | Int-Salim (SALUD E IMAGINACIÓN, S.L.) |
| D22 | Levadiet-C | Flakes | DIETISA |
| D23 | “Cerveza biológica” | Liquid | RAPUNZEL |
Brewer’s yeast and wheat germ;
Brewer’s yeast;
Yeast;
Yeast and germ;
Yeast flakes;
Yeast alive;
Biological beer.
S. cerevisiae strains used as control and assays for which they were used.
| Strain | Origin | Reportedvirulence-associatedphenotypes | Reported | Reference | Use in this work |
| “Ultra-Levura” | Commercial | Growth at 42°C, proteaseand phospholipasesecretion andPh growth | Moderatelyvirulent |
| Control in the |
| 102 | Respiratory | Growth at 42°C, proteaseand phospholipasesecretion, Ph and invasivegrowth | Virulent |
| Control in the |
| CECT 10.431 | Wine | Low invasivegrowth | Non-virulent |
| Control in the |
| YJM128 | Lung | Growth at42°C, proteasesecretion, Phand invasivegrowth | Virulent |
| Control in the |
| W303 | Laboratory | n.r. | n.r. | - | Control in the |
| BY4741 | Laboratory | n.r. | n.r. | - | Control in the |
(named D5 in Table 1);
Molecular characterization of these strains have been described previously [44];
Growth at different temperatures,
protease and phospholipase secretion, Ph (pseudohyphal) and invasive growth;
MAPK activation;
Adherence to plastics;
In vivo study by intravenous inoculation of strains in BALB/c mice;
(MAT a ; ura3-52; trp1D2; leu2-3_112; his3-11; ade2-1; can1-100) [64], [76];
(MAT a his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) (EUROSCARF); n.r.: Non reported.
Figure 1Molecular characterization of yeast strains analyzed.
HinfI mtDNA restriction patterns of yeasts isolated from commercial products (A) and of yeast strains used as controls (B); δ-PCR amplification patterns of yeasts isolated from commercial products (C). The DNA of phage λ digested with Pst I and a 100-bp DNA ladder marker (Invitrogen Life Technologies) served as the size standard respectively.
Distribution of DNA types of yeasts isolated from commercial products.
| mt DNA pattern | δ PCR pattern | Composite pattern | Product code |
| Am | Aδ | Am/Aδ | D2 |
| Am | Bδ | Am/Bδ | D3, D4, D7, D8 |
| Bm | Cδ | Bm/Cδ | D5 |
| Cm | Dδ | Cm/Dδ | D6 |
| Dm | Eδ | Dm/Eδ | D14 |
| Em | Fδ | Em/Fδ | D23 |
Figure 2Growth at different temperatures of commercial and control S. cerevisiae strains.
Ten-fold serial dilutions of the indicated strains were dropped on YPD plates and incubated for 24 h at 30, 37, 39 and 42°C. +++: growth in all the dilutions; ++: growth in the first two dilutions; +: growth in the first dilution; ±: growth in the first drop without dilution; –: no growth.
Figure 3Generation time of commercial and control S. cerevisiae strains on YPD at 30°C and 37°C.
Error bars correspond to standard deviations. ∧not determined. *p<0.05 with regard to the avirulent strains (CECT 10.431 and W303), as assessed by Students t-test.
Figure 4Extracellular secretion of phospholipase (A) and protease (B) of commercial and control S. cerevisiae strains.
Activity is expressed as Pz value (see Material and Methods section) and the level of activity is indicated between brackets according the following code: Pz = 1 (Negative activity: –); 0,99≥Pz≥0,70 (Low activity: +); 0,69≥Pz≥0,50 (Moderate activity: ++); Pz≤0,50 (High activity: +++). ∧not determined (these strains were unable to growth at the optimum temperature to determine this activity). Results are expressed as the mean ± SD.
Figure 5Differences in pseudohyphal growth of commercial and control S. cerevisiae strains in SLAD medium.
Examples of colony morphologies of pseudohyphal growth: (Ph −) absence of pseudohyphal growth, (Ph +) intermediate pseudohyphal development, (Ph ++) high pseudohyphal development. The images were taken with a Leica Camera associated with a microscope Leica HPS60 at 40X magnification.
Figure 6Examples of invasive growth in commercial and control S. cerevisiae strains.
Three degrees of invasiveness were determined based on the residual growth remained after washing. Invasive growth (+): yeast cells attached to the agar surface; Invasive growth (±): yeast cells partially anchored to the agar; Invasive growth (–): yeast cells fully eliminated.
Colony phenotype switching frequencies of commercial Saccharomyces strains.
| Principal phenotype | Secondary phenotypes | ||||||||
| Strain | Colony number (frequency) | Colony number (frequency) | |||||||
| D2 |
|
|
|
|
|
|
|
|
|
| 10.332 (0.99) | 71 (6.78×10−3) | 31 (2.96×10−3) | 10 (9.56×10−4) | 3 (2.87×10−4) | 7 (6.69×10−4) | 2 (1.91×10−4) | 2 (1.91×10−4) | 2 (1.91×10−4) | |
| D4 |
|
|
|
|
|
| |||
| 7715 (0.95) | 65 (7.98×10−3) | 284 (3.48×10−2) | 7 (8.59×10−4) | 6 (7.36×10−4) | 73 (8.96×10−3) | ||||
| D14 |
|
|
|
|
|
|
|
| |
| 6565 (0.99) | 18 (2.27×10−3) | 4 (6.06×10−4) | 2 (3.03×10−4) | 3 (4.54×10−4) | 6 (9.09×10−4) | 2 (3.03×10−4) | 1 (1.51×10−4) | ||
| D23 |
|
|
|
|
|
|
|
| |
| 8284 (0.96) | 287 (3.32×10−2) | 13 (1.50×10−3) | 19 (2.20×10−3) | 2 (2.31×10−4) | 12 (1.39×10−3) | 23 (2.66×10−3) | 2 (2.31×10−4) | ||
Colony phenotype descriptions: D2-A (5–7 mm, light pink, strong pink centre, white edge, creamy texture); D2-B (5–7 mm, light pink, strong pink centre, white edge, strong pink sector, creamy texture); D2-C (5–7 mm, strong pink, white edge, rough texture, striated); D2-D (3 mm, light pink, strong pink centre, creamy texture); D2-E (5–7 mm, light pink, strong pink centre, white edge, creamy texture, star shape); D2-F (5–7 mm, light pink, strong pink centre, white edge, white sector, creamy texture); D2-G (3 mm, strong pink, creamy texture, irregular); D2-H (4 mm, light pink, strong pink centre, white edge, strong pink sector, rough texture); D2-I (5–7 mm, light pink, strong pink centre, rough texture, striated); D4-A (5 mm, light pink, strong pink centre, creamy texture); D4-B (2 mm, light pink, strong pink centre, creamy texture, irregular); D4-C (1 mm, light pink, creamy texture, irregular); D4-D (3 mm, strong pink, creamy texture); D4-E (5 mm, light pink, strong pink centre, creamy texture, white sector); D4-F (5 mm, light pink, strong pink centre, creamy texture, irregular); D14-A (5 mm, light pink, pale pink centre, strong pink edge, creamy texture); D14-B (2–3 mm, pale pink, creamy texture); D14-C (2–3 mm, light pink, pale pink centre, creamy texture); D14-D (5 mm, light pink, pale pink centre, strong pink edge, creamy texture, white sector); D14-E (5 mm, light pink, pale pink centre, strong pink edge, creamy texture, strong pink sector); D14-F (5 mm, medium pink, pale pink centre, strong pink edge, creamy texture); D14-G (5 mm, light pink, pale pink centre, strong pink edge, creamy texture, striated); D14-H (2 mm, pale pink, dark pink edge, creamy texture); D23-A (4–5 mm, light pink, strong pink centre, creamy texture); D23-B (1–2 mm, strong pink, creamy texture); D23-C (4–5 mm, light pink, strong pink centre, creamy texture, irregular); D23-D (4 mm, strong pink, creamy texture); D23-E (7–8 mm, light pink, strong pink centre, creamy texture); D23-F (4–5 mm, light pink, strong pink centre, rough texture, striated); D23-G (5 mm, light pink, strong pink centre, strong pink sector, creamy texture); D23-H (1–2 mm, light pink, strong pink centre, creamy texture).
Figure 7Differences in phosphorylation of MAPKs Slt2 and Kss1 in dietary Sacharomyces strains.
Phosphorylation of MAPKs Slt2 and Kss1 in extracts from the indicated commercial S. cerevisiae strains growing at 24°C and from the laboratory BY4741 strain, growing both at 24°C and 39°C. Phospho-Kss1 and phospho-Slt2 were detected by immunoblotting analysis with anti-phospho-p42/44 and the protein load monitored using anti-Slt2, anti-Kss1 and anti-actin antibodies.
Figure 8Adherence of commercial and control yeast strains to plastic and catheters.
(A) Percentage of cells of the different yeast strains adhered to polystyrene Petri plates incubated 1 h at 37°C with 5% CO2 in glucosaline solution. (B) Adherence of yeast strains to polystyrene microtiter plates incubated 1 h at 37°C with 5% CO2 in glucosaline solution determined by absorbance. (C) Adherence of yeast strains to sections (1 cm) of polyurethane intravenous catheters incubated 1 and 24 h at 37°C in glucosaline solution and RPMI. First bar: 1 h, glucosaline solution; Second bar: 24 h, glucosaline solution; Third bar: 1 h, RPMI medium; Fourth bar: 24 h, RPMI medium).
Virulence-associated phenotypes observed in strains isolated from commercial products.
| Strain | Growth at: | Enzymatic activity | Growth | Switching | MAPK activation | Plastics ADH | % Positivity | |||||
| 37°C | 39°C | 42°C | Protease | PLA | Ph | Invasive | Slt2 | Kss1 | ||||
| D2 | + | + | + | + | + | + | − | + | − | − | + | 72.7 |
| D4 | + | + | − | + | + | + | − | + | − | − | + | 63.6 |
| D14 | + | + | + | + | + | + | − | + | + | − | − | 72.7 |
| D6 | − | − | − | n.d. | + | − | + | n.d. | + | − | + | 44.4 |
| D23 | − | − | − | n.d. | + | − | − | + | − | − | − | 20.0 |
Phenotype traits shown in Figures (2, 4, 5, 6, 7, 8) and Table 4 were simplified as follows to calculate the Spearman’s Rho correlation coefficients between strains and apply the Jaccard proximity test (excluding joint absences for considerations): growth at 37, 39 and 42°C, +++, ++ and + were simplified to +, and ± and − were simplified to −; phospholipase activity (PLA), ++ and + were simplified to +; pseudohyphal (Ph) growth,++ and + were simplified to +; invasive growth, ± and − were simplified to −; switching, multiple colony phenotypes with frequencies between 10−2−10−4 were considered +; MAPK activation, high Slt2 and Kss1 phosphorylation was considered + and low or non phosphorylation were considered −; Plastics adherence (ADH), Petri plates adherence values >30% and microtiter plates absorbance values >1 were considered +, Petri plates adherence values ≤30% and microtiter plates absorbance values <1 were considered −. n.d. not determined.
Figure 9Kaplan-Meier plot of the cumulative mortality of BALB/c mice intravenously challenged with Saccharomyces strains.
(A) D14 survival curve representing the combination of four experiments was compared to that of the rest of dietetic strains (D2, D4, D23) and control strains (CECT 10.431, W303, YJM128); (B) Comparison of D14 survival curves obtained in four independent trials.
Figure 10Comparative burdens of Saccharomyces strains recovered in brains and kidneys after intravenous infection of BALB/c mice.
Day +7: D2, D4, W303 and CECT 10.431 (n = 4 each); D14 and D23 (n = 6 each); YJM118 (n = 10). Day +15: W303 (n = 3); D2, D4 and CECT 10.431 (n = 4 each); D14 and D23 (n = 7 each); YJM118 (n = 9). Day +30: W303 (n = 3); D2, D4, D23 and CECT 10.431 (n = 6 each); D14 and YJM128 (n = 11). Results are expressed as the mean ± SD.
Figure 11Evaluation of the presence of yeasts in mouse feces during the assay of gastrointestinal infection.
Fecal counts of dietetic strains D14 (♦) and D23 (▪) after oral administration of ICR/Swiss mice receiving antibiotic supplementation in the drinking water and immunosuppressant intraperitoneally are shown. Each point represents the mean of 12 mice (day 1), 6 mice (day 3), 5 mice (day 5) and 4 mice (day 7). Results are expressed as the mean ± SD. (D): Dexamethasone injected intraperitoneally.
Intestinal translocation and dissemination of isolates D14 and D23 based on the number of mice that showed yeast burdens in target organs.
| No. of mice with D14/total sacrificed mice (%) | No. of mice with D23/total sacrificed mice (%) | |||||
| Day ofsacrifice | Peyer’spatches | MLNs | Otherorgans | Peyer’spatches | MLNs | Otherorgans |
| Day 5 | 4/4 (100) | 1/4 (25) | 3/4 (75) | 3/4 (75) | 0/4 (0) | 3/4 (75) |
| Day 6 | 4/4 (100) | 2/4 (50) | 3/4 (75) | 4/4 (100) | 0/4 (0) | 0/4 (0) |
| Day 7 | 4/4 (100) | 1/4 (25) | 3/4 (75) | 2/4 (50) | 0/4 (0) | 0/4 (0) |
|
|
|
|
|
|
|
|
Day of sacrifice after initiation of oral administration of the yeast.
MLNs: mesenteric lymph nodes.
Other organs: brain, kidneys, liver.
Figure 12Translocation and dissemination from the gut of strains D14 and D23 after oral inoculation.
Burdens of dietetic strains D14 (A) and D23 (B) are shown after oral administration of ICR/Swiss mice receiving antibiotic supplementation in the drinking water and immunosuppressant intraperitoneally. Each bar represents polled data from 2 to 4 mice and exceptionally from 1 mouse (asterisk). Results are expressed as the mean ± SD.
Statistical analysis of association between virulence-associated phenotypic traits and in vivo virulence.
|
| ||
| Traits tested | Jaccardproximities | Spearman’s Rho(significance) |
| Growth at 39°C | 1.000 | 1.000 ( |
| Pseudohyphal growth | 1.000 | 1.000 ( |
| Protease activity | 0.800 | 0.730 ( |
| Growth at: | ||
| 42°C | 0.750 | 0.750 ( |
| 37°C | 0.667 | 0.471 ( |
| Phospholipase activity | 0.600 | 0.417 ( |
| Switching | 0.600 | 0.417 ( |
| Plastic adherence | 0.500 | 0.548 ( |
| Invasive growth | 0.250 | 0.354 (p = 0.437) |
| MAPK activation: | ||
| Slt2 | 0.250 | 0.354 ( |
| Kss1 | 0.000 | n.c. |
Traits ordered by proximity for better comprehension. Data used in the case of strains isolated from dietary supplements are shown in Table 5. Phenotypic traits of control strains, simplified following the codes in Table 5, are: YJM128 (+, +, +, +, –, +, +, n.d., n.d., n.d., n.d.), W303 (+, –, –, +, –, –, –, n.d., n.d., n.d., –), CECT 10.431 (+, –, –, –, –, –, –, n.d., n.d., n.d., n.d.). Data of YJM128 have been obtained previously [28]. “+” and “–” were coded numerically as “1” and “0” respectively for statistical analysis.
In vivo virulence determined by intravenous inoculation of strains D2, D4, D14, D23, YJM128, W303 and CECT 10.431 in BALB/c mice. Virulence was simplified as follows: high burdens levels in brain (3.18 to 5.31 mean log10 CFU) at 7 and 15 days post-infection were considered + and lower burdens levels and the inability to colonize was considered –.
A proximity value of “1” indicates the maximum association and value “0” indicates the opposite. Jaccard proximities were calculated excluding joint absences from consideration.
Values of “1” indicates perfect correlation and “0″ indicates no relationship.
n.c. Spearman’s correlation cannot be calculate because this trait shows constant values (see Table 5).